Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00275210
Registration number
NCT00275210
Ethics application status
Date submitted
3/01/2006
Date registered
11/01/2006
Date last updated
20/04/2009
Titles & IDs
Public title
MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
Query!
Scientific title
Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
Query!
Secondary ID [1]
0
0
EFC3313
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colonic Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Oxaliplatin (SR96669)
Treatment: Drugs: Oxaliplatin (SR96669)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To to detect occurrence of relapse the following examinations have to be performed for 5 years:
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Primary outcome [2]
0
0
Every 6 months for ultrasound or abdominopelvic CT scan and CEA determination,
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Primary outcome [3]
0
0
Every year for chest X-ray and colonoscopy for non polyp free patient,
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Query!
Primary outcome [4]
0
0
Every 3 years colonoscopy for polyp free patient
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Query!
Secondary outcome [1]
0
0
Every 2 weeks clinical and laboratory tests (hematological, creatinine and liver tests) for safety evaluation during treatment then every 6 months neurological examination Date of death for OS
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
Main selection criteria:
- Histologically proven stage Dukes " B2 " (stage II: T3-T4 N0 M0) and " C " (stage III:
any T N1-2 M0) colon carcinoma. The inferior pole of the tumor must be above the
peritoneal reflection (> 15 cm from the anal margin)·
- Complete resection of the primary tumor without gross or microscopic evidence of
residual disease
- Treatment within 7 weeks following surgery
- Age 18-75 years old
- ECOG PS £ 2
- No prior chemo, immuno or radiotherapy
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/1998
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2003
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2246
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
sanofi-aventis Australia & New Zealand administrative office - Macquarie Park
Query!
Recruitment postcode(s) [1]
0
0
- Macquarie Park
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Wien
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Diegem
Query!
Country [3]
0
0
Denmark
Query!
State/province [3]
0
0
Horsholm
Query!
Country [4]
0
0
France
Query!
State/province [4]
0
0
Paris
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Berlin
Query!
Country [6]
0
0
Greece
Query!
State/province [6]
0
0
Athens
Query!
Country [7]
0
0
Hungary
Query!
State/province [7]
0
0
Budapest
Query!
Country [8]
0
0
Israel
Query!
State/province [8]
0
0
Natanya
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
Milano
Query!
Country [10]
0
0
Netherlands
Query!
State/province [10]
0
0
Gouda
Query!
Country [11]
0
0
Norway
Query!
State/province [11]
0
0
Lysaker
Query!
Country [12]
0
0
Poland
Query!
State/province [12]
0
0
Warszawa
Query!
Country [13]
0
0
Portugal
Query!
State/province [13]
0
0
Porto Salvo
Query!
Country [14]
0
0
Singapore
Query!
State/province [14]
0
0
Singapore
Query!
Country [15]
0
0
Spain
Query!
State/province [15]
0
0
Barcelona
Query!
Country [16]
0
0
Sweden
Query!
State/province [16]
0
0
Bromma
Query!
Country [17]
0
0
Switzerland
Query!
State/province [17]
0
0
Geneva
Query!
Country [18]
0
0
United Kingdom
Query!
State/province [18]
0
0
Guildford Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate the FOLFOX regimen versus LV5FU2 in the adjuvant treatment of stage II and III
colon cancer.
Primary objective: Disease Free Survival (DFS) Secondary objective: Overall Survival (OS),
safety (including long term toxicity)
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00275210
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Aimery de Gramont, MD
Query!
Address
0
0
Hopital saint-Antoine, Oncology department
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00275210
Download to PDF